学术主导临床试验中基于风险监查的实施障碍与促进因素:一项混合方法研究
该研究采用混合方法解释性序列设计,先对爱尔兰132名学术临床研究者进行问卷调查,再对22人进行半结构访谈,识别学术主导临床试验中实施基于风险监查(RBM)的障碍与促进因素。障碍包括缺乏RBM知识/培训、IT需求增加导致成本上升、试验人员工作量增加及缺乏RBM有效性的证据;促进因素包括ICH-GCP指南下的法律义务、RBM指南的可获得性及对未来节省成本的认知。结论认为需要培训和监管认可的指南来支持RBM在学术主导临床试验中的实施。
要点
- 13%(18/132)的应答者不熟悉基于风险监查(RBM)这一术语,仅21%(28/132)曾在临床试验中实施过RBM。
- RBM实施障碍包括缺乏知识/培训、IT需求增加致成本上升、试验人员工作量增加及缺乏有效性证据。
- 促进因素包括ICH-GCP指南下的法律义务、RBM指南的可获得性及对未来节省成本的认知。
核心结论
- 研究结果表明需要培训和监管认可的指南来支持RBM在学术主导临床试验中的实施。
- 研究为政策制定者和临床试验监管机构改进RBM采纳的干预和策略提供了有价值的见解。
研究设计与样本
- 采用混合方法解释性序列设计,先进行定量调查,随后进行半结构访谈。
- 对爱尔兰132名学术临床研究者进行问卷调查,调查应答率为49%(132/273)。
- 从调查参与者中目的性抽样22人进行访谈,以深入理解定量发现。
- 调查和访谈数据合并生成RBM实施的感知障碍和促进因素列表,并提出相关建议和解决方案。
主要发现
- 13%(n=18)的应答者不熟悉基于风险监查(RBM)这一术语。
- 不到四分之一(21%,n=28)的应答者曾在临床试验中实施过RBM。
- RBM实施障碍包括缺乏RBM知识/培训、IT需求增加导致成本上升、试验人员工作量增加及缺乏支持RBM作为有效监查方法的证据。
- 促进因素包括根据新的ICH-GCP指南参与者有法律义务实施RBM、RBM指南的可获得性及对未来试验中实施RBM可节省成本的认知。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In November 2016, the ICH published a requirement for sponsors to develop a systematic, prioritised, risk-based approach to monitoring clinical trials. This approach is more commonly known as risk-based monitoring (RBM). However, recent evidence suggests that a 'gold standard', validated approach to RBM does not exist and it is unclear how sponsors will introduce RBM into their organisations. A first step needed to inform the implementation of RBM is to explore academic trialists' readiness and ability to perform RBM. The aim of this paper is to identify the attitudes and perceived barriers and facilitators to the implementation of RBM in academic-led clinical trials in Ireland. METHODS: This is a mixed-methods, explanatory sequential design, with quantitative survey followed by semistructured interviews. Academic clinical researchers (N = 132) working in Ireland were surveyed to examine their use and perceptions of RBM. A purposive sample of survey participants (n = 22) were then interviewed to gain greater insight into the quantitative findings. The survey and interview data were merged to generate a list of perceived barriers and facilitators to RBM implementation, with suggestions for, and solutions to, these issues. RESULTS: Survey response rate was 49% (132/273). Thirteen percent (n = 18) of responders were not familiar with the term risk-based monitoring and less than a quarter of respondents (21%, n = 28) had performed RBM in a clinical trial. Barriers to RBM implementation included lack of RBM knowledge/training, increased costs caused by greater IT demands, increased workload for trial staff and lack of evidence to support RBM as an effective monitoring approach. Facilitators included participants' legal obligation to perform RBM under the new ICH-GCP guidelines, availability of RBM guidance and perception of cost savings by performing RBM in future trials. CONCLUSION: The results of this study demonstrate a need for training and regulatory-endorsed guidelines to support the implementation of RBM in academic-led clinical trials. The study provides valuable insights to inform interventions and strategies by policy-makers and clinical trial regulators to improve RBM uptake.
引用
- Hurley C, Sinnott C, Clarke M, et al. Perceived barriers and facilitators to Risk Based Monitoring in academic-led clinical trials: a mixed methods study. Trials. 2017. PMID: 28893317. doi:10.1186/s13063-017-2148-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。